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Abstract: Cycloid psychoses (CP) differ from schizophrenia regarding symptom profile, 
course, and prognosis and over many decades they were thought to be a separate entity within 
the psychosis spectrum. As to schizophrenia, research into the pathophysiology has focused on 
dopamine, brain-derived neurotrophic factor, and glutamate signaling in which, concerning the 
latter, the N-methyl-d-aspartate receptor plays a crucial role. The present study aims to determine 
whether CP can biochemically be delineated from schizophrenia. Eighty patients referred for 
psychotic disorders were assessed with the Comprehensive Assessment of Symptoms and His-
tory, and (both at inclusion and after 6 weeks of antipsychotic treatment) with the Positive and 
Negative Syndrome Scale and Clinical Global Impression. From 58 completers, 33 patients were 
diagnosed with schizophrenia and ten with CP according to the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition, and Leonhard criteria, respectively. Fifteen patients were 
diagnosed with other disorders within the psychosis spectrum. At both time points, blood levels 
of the dopamine metabolite homovanillic acid, brain-derived neurotrophic factor, and amino acids 
related to glutamate neurotransmission were measured and compared with a matched control 
sample. Patients with CP showed a significantly better response to antipsychotic treatment as 
compared to patients with schizophrenia. In CP, glycine levels were elevated and tryptophan 
levels were lowered as compared to schizophrenia. Glutamate levels were increased in both 
patient groups as compared to controls. These results, showing marked differences in both treat-
ment outcome and glutamate-related variable parameters, may point at better neuroplasticity in 
CP, necessitating demarcation of this subgroup within the psychosis spectrum.
Keywords: cycloid psychoses, schizophrenia, glutamate, glycine, tryptophan, neuroplasticity
Introduction
Over many decades, dopamine (DA) neurotransmission has been thought to be the 
main mechanism in the pathophysiology of psychotic disorders, and DA receptor 
antagonists have been demonstrated to be effective in reducing – mainly positive – 
psychotic symptoms.1 Subsequent research has disclosed that other neurotransmitter 
systems, particularly that of glutamate, are associated with negative symptoms and 
cognitive dysfunctions via the N-methyl-d-aspartate (NMDA) receptor.2–5
Glutamate is the most abundant excitatory neurotransmitter in human brain, and 
glutamatergic receptors are involved in regulating neuronal migration, growth, and 
pruning (ie, neuroplasticity).6,7 Glutamate acts at different types of receptors, of which 
the NMDA receptor is the most investigated.8,9 Glycine acts as a co-agonist at the 
NMDA receptor and can potentiate glutamatergic neurotransmission.10 In contrast, 
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antagonizing the NMDA receptor by means of phencyclidine 
or ketamine induces schizophrenia-like symptoms.11,12
These observations have led to the hypothesis that the 
pathophysiology of schizophrenia is at least partly related 
to impairment in NMDA neurotransmission.13,14 Hence, it 
seems likely that enhancing NMDA activity might benefit 
patients with schizophrenia, which could possibly be 
achieved by administering components targeting the gluta-
mate system.8,10,15,16
Cycloid psychoses (CP) as described by Leonhard in 
the 1950s, partly operationalized by Perris and Brockington 
and included in the International Classification of Dis-
eases, Tenth Edition, as acute polymorphic psychotic dis-
orders, differ from schizophrenia with respect to symptom 
profile, course, and prognosis.17–20 According to Leonhard, 
three subtypes can be delineated: anxiety–happiness 
psychosis, confusion psychosis, and motility psychosis, all 
showing a pleiomorphic symptom profile with intraphasic 
bipolarity. In general, full recovery is reached without resid-
ual negative symptoms or cognitive decline.21–23 CP, as such, 
are not included in the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition (DSM-IV), although 
pananxiety, perplexity, and motility disorders have been 
demonstrated in a substantial percentage of patients.24–30 
An overview of the characteristics of schizophrenia and CP 
is presented in Table 1.
Since CP differ significantly from schizophrenia, the 
hypothesis was formulated that they could also be distinct on 
their biochemical profile, especially regarding glutamatergic 
transmission. Therefore, in the present study, peripheral 
levels of amino acids related to glutamate signaling (ie, 
glutamate, glycine, and tryptophan) were measured in a 
group of patients with psychosis spectrum disorders. In 
addition, levels of brain-derived neurotrophic factor (BDNF) 
and the DA metabolite homovanillic acid (HVA) were 
determined, reflecting neuroplasticity and dopaminergic 
activity, respectively.
Methods
Patients
Patients were recruited over a 2.5-year period at the Vincent 
van Gogh Institute for Psychiatry. Included were adult male 
and female patients meeting DSM-IV criteria for psychosis 
spectrum disorders, who required antipsychotic treatment 
intervention. Intervention was defined as start or switch of 
antipsychotic agent or use of augmentation strategies. Exclu-
sion criteria were known genetic syndromes or intellectual 
disability, and somatic or neurologic disorders interfering with 
treatment as usual. Research was performed in accordance with 
the Declaration of Helsinki and was approved by the regional 
ethics committee (METiGG) and board of directors of Vincent 
van Gogh Institute. Written informed consent was obtained fol-
lowing Dutch ethical guidelines (CCMO registration number 
NL20469.097.07). After inclusion, all patients were prescribed 
first-generation antipsychotic (FGA) or second-generation 
antipsychotic (SGA) agents by their treating psychiatrist fol-
lowing standard professional guidelines. Concomitant treat-
ment with two antipsychotic agents, mood stabilizer, and/or 
antidepressant was allowed and documented.
During the study period, 194 patients were identified as 
eligible for inclusion. However, from these 194 patients, 71 
were considered unable to provide informed consent because 
of severity of illness. In another 23 patients, the intended 
pharmacological intervention was not performed, yielding 
100 patients who were eligible for inclusion. Twenty patients 
refused to participate, mostly because of the need for veni-
puncture, resulting in a study group of 80 patients. Of them, 
58 completed all clinical and biochemical assessments at 
baseline and after 6 weeks.
Diagnostic procedures
All patients were assessed by the first author (NvdK) before 
or within 1 week after start of treatment with antipsychotics. 
At baseline, the Comprehensive Assessment of Symptoms 
and History was applied to establish diagnoses according 
Table 1 Characteristic differences between schizophrenia and cycloid psychoses
Schizophrenia Cycloid psychoses
Onset Slow and insidious (weeks to months) Often acute (hours to days)
Age at onset Adolescence/young adulthood Any age
Symptomatology Delusions, hallucinations, disorganization, 
negative symptoms
Perplexity, confusion, mood swings, motility disorders, 
hallucinations, ideas of self-sacrifice
Course Relapsing and remitting, chronic, gradual 
functional and cognitive decline
Full remission, relapsing course without negative or 
cognitive decline
Prognosis Unfavorable Favorable
Treatment Antipsychotic agents Low-potent antipsychotic agents in acute phase, limited 
evidence for maintenance treatment (lithium carbonate)
Sex distribution Male ≈ female Male , female
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to DSM-IV.31 The Positive and Negative Syndrome Scale 
(PANSS) and Clinical Global Impression of Severity and 
Improvement (CGI-S/I) were used to measure symptom 
profile and overall disease severity at baseline and after 
6 weeks.32,33 PANSS cognitive score was calculated 
according to the procedure as described by Lindenmayer 
et al.34 To establish diagnosis of CP, a symptom checklist 
according to Leonhard was completed by NvdK and a cli-
nician (MKF Schneider) trained in establishing diagnoses 
according to Leonhard.26,30,35 Final diagnoses were made in 
a so-called Longitudinal Evaluation of All Data (LEAD) 
conference, in which all possible and probable cases of 
CP were discussed with two experts in the field of CP (GS 
and WV).36
Biochemical analyses
Patients
Blood samples were collected by means of venipuncture 
between 8 and 10 am at both assessment dates to determine 
BDNF, HVA, the amino acids glutamate, glycine, and tryp-
tophan, and the ratio between tryptophan and the five large 
neutral amino acids (LNAAs) competing for the same trans-
port system, being leucine, isoleucine, valine, phenylalanine, 
and tyrosine (Trp/LNAAs ratio).
Plasma was obtained after centrifugation of ethylenedi-
aminetetraacetic acid blood for 20 minutes at 2,650× g and 
20°C, and stored at -80°C until analysis. All biochemical 
analyses were performed at the Neuropsychiatric Laboratory 
of Erasmus University Medical Center, Rotterdam, and the 
technician was blinded to the clinical situation and diagnosis 
of the patients.
Plasma was deproteinized, and amino acids were 
separated by high-performance liquid chromatography and 
detected by fluorescence after derivatization with ortho-
phthaldialdehyde as described previously.37 HVA levels 
were measured after deproteinization of plasma by high-
performance liquid chromatography using a Zorbax Eclipse 
XDB-C8 column (5 μm particle size, 250×3 mm; Agilent 
Technologies, Santa Clara, CA, USA) for separation. For the 
detection of HVA, an electrochemical detector (oxidation 
potential was set to 0.7 V) and the Intro controller (Antec 
Leyden, Zoeterwoude, the Netherlands) were used. Quanti-
fication was done by measuring peak heights relative to two 
internal standards (isoprenaline and 5-methylserotonin). The 
mean recovery (±standard deviation [SD]) of HVA added 
to the plasma samples was 95%±7%. BDNF was measured 
in serum by a double-antibody sandwich enzyme-linked 
immunosorbent assay (Promega Corporation, Madison, 
WI, USA).
Controls
Biochemical parameters from age-matched controls 
were taken from a large database of the aforementioned 
Neuropsychiatric Laboratory. Age-matched controls were 
taken from a large database, consisting of hospital staff and 
students and subjects from the general community, all with-
out a personal or family history of psychiatric illness. Mean 
age of the control group (n=75) was 37.9±10.1 years.
Statistics
From the 58 completers, only patients with a diagnosis of 
schizophrenia (n=33) or CP (n=10) were included in the 
statistical analyses. To compare means, nonparametric Mann–
Whitney U test was used for non-normally distributed data (bio-
chemical parameters), whereas Student’s t-test was applied for 
normally distributed data. To investigate changes between time 
points, Wilcoxon signed rank test (biochemical parameters) or 
paired t-test (PANSS scores) was used. For binary variables, a 
chi-square test was done. Significance was set at P,0.05. All 
data are presented as mean ± SD, unless stated otherwise.
Results
Patients
By excluding patients diagnosed with other psychotic disor-
ders (n=15), the study sample (n=43) consisted of 30 males and 
13 females with a mean age of 34.8±11.3 years. Thirty-three 
patients received a diagnosis of schizophrenia, and in ten, a 
diagnosis of CP according to Leonhard was made (anxiety–
happiness: n=5; confusion: n=2; motility: n=3). Mean age at 
first psychosis was 26.5±9.8 years, and mean duration of psy-
chotic illness was 8.3±8.1 years. Fourteen patients (CP: n=5; 
schizophrenia: n=9) did not receive psychotropic medication 
prior to inclusion in the study (referred to as “at baseline”), of 
which eight were antipsychotic naïve (CP: n=3; schizophrenia: 
n=5). Eight out of the total of 43 patients were first-episode 
psychosis (FEP) patients. Five patients were classified as both 
medication naïve and having FEP (CP: n=3; schizophrenia: 
n=5). Details on symptom clusters, effect of antipsychotic 
treatment, and severity of illness are summarized in Table 2.
Since each patient received an individually targeted treat-
ment, data were scrutinized for possible confounding effects of 
psychopharmacological heterogeneity. With respect to the two 
patient groups (CP: n=10; schizophrenia: n=33), no differences 
were found as to medication status (naïve, free .2 weeks, or 
medicated), use of co-medication (antidepressant or mood 
stabilizers), and antipsychotic class (FGA or SGA). Regarding 
the latter, in the CP group, none of the patients was treated with 
clozapine, whereas nine patients in the schizophrenia group 
did receive this agent. The CP group comprised significantly 
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patients with CP as compared to controls but differed only 
at baseline from the schizophrenia group. Trp/LNAAs ratio 
was lowered in both patient groups as compared to controls. 
Plasma levels of HVA did not differ between the groups. All 
data are presented in Table 3.
In both the subgroup of patients with schizophrenia who 
were treated with clozapine (n=9) and the subgroup of eight 
medication-naïve patients (CP: n=3; schizophrenia: n=5), low-
ered serum levels of BDNF and elevated levels of glutamate 
were found at both time points. However, in the clozapine sub-
group, glycine levels were significantly lowered as compared 
to controls at baseline (177.6±45.1 versus 224.2±47.8 μmol/L), 
whereas in the medication-naïve subgroup, glycine levels did 
not differ from controls at both time points.
The 15 patients with diagnoses other than CP or schizo-
phrenia (schizoaffective disorder: n=1; bipolar disorder: 
n=5; delusional disorder: n=1; brief psychotic disorder: n=2; 
schizotypal personality disorder: n=1, psychotic disorder 
not otherwise specified: n=5) were analyzed separately. 
Glutamate levels were significantly elevated as compared to 
controls at both time points. Data on biochemical parameters 
in this group are depicted in Table 4.
As to intercorrelations of biochemical and clinical par a-
meters, both in the total patient sample and in the schizo-
phrenia subgroup, baseline glutamate levels were positively 
correlated with changes in PANSS cognitive scores (total 
sample: T=0.280, P=0.012; schizophrenia: T=0.360, 
P=0.005). Glutamate levels after 6 weeks were positively 
correlated with PANSS cognitive scores at both time points in 
the total patient group (baseline: T=0.221, P=0.043; 6 weeks: 
T=0.279, P=0.011) and with PANSS cognitive scores after 
6 weeks in schizophrenia patients (T=0.289, P=0.023).
Baseline glycine levels did not correlate with any of the 
clinical (sub)scales. Glycine levels after 6 weeks correlated 
significantly with changes in PANSS cognitive scores 
(T=0.523, P=0.038) in CP patients. No other correlations 
were found in CP between glutamate or glycine levels and 
other PANSS or CGI scores at both time points.
No significant correlations were found for (changes in) 
any of the biochemical parameters from Table 3 and (changes 
in) other clinical parameters (PANSS or CGI) in the two 
subgroups at both time points.
Discussion
In this study, patients with CP and schizophrenia were 
assessed on both clinical and biochemical profiles. Essen-
tially, the CP group showed better clinical outcome than the 
schizophrenia group and differed significantly in terms of 
Table 2 Demographic and clinical parameters in patients with CP 
and schizophrenia
CP (n=10) Schizophrenia (n=33)
Male/female* 4/6 26/7
Age* 42.3±10.3 32.6±10.8
Age at onset* 36.7±10.8 23.4±7.1
FEP, yes/no** 5/5 3/30
Smoking, yes/noa,* 3/7 25/8
Caffeine, yes/noa 9/1 29/4
Soft drugs, yes/noa 1/9 7/26
Hard drugs, yes/no 0/10 2/31
PANSS baselineb
Total score* 77.2±19.1 92.9±17.4
Positive subscale* 20.2±5.8 25.0±5.5
Negative subscale** 16.6±5.8 22.9±6.8
Global subscale 40.4±11.7 45.1±9.1
Cognitive subscale 13.1±4.4 15.3±3.9
PANSS 6 weeksb
Total score* 55.4±22.2 75.3±13.3
Positive subscale** 11.5±6.5 18.9±5.2
Negative subscale* 13.8±6.1 19.4±5.1
Global subscale 30.1±11.7 37.0±6.9
Cognitive subscale* 9.8±4.5 13.1±3.4
Mean CGI severityb
Baseline 4.0±1.2 4.9±1.1
6 weeks* 2.5±1.4 4.0±1.1
Mean CGI improvementb 2.4±1.0 2.9±0.9
Notes: aSmoking and use of caffeine/soft drugs/hard drugs were defined as any 
use ≠ 0 in the past month, as reported by the patient. bClinical data presented as 
mean ± SD. All within-group differences between PANSS and CGI scores at baseline 
and after 6 weeks are significant (P#0.001) except for PANSS negative score in the 
CP group (P=0.062). *Difference between CP and schizophrenia (Mann–Whitney U), 
P,0.05. **Difference between CP and schizophrenia (Mann–Whitney U), P#0.01.
Abbreviations: CP, cycloid psychoses; FEP, first-episode psychosis; PANSS, Positive 
and Negative Syndrome Scale; CGI, Clinical Global Impression; SD, standard 
deviation.
more females, who had higher ages at first presentation of 
psychotic illness as well as at time of inclusion. Finally, five 
patients with CP were defined as FEP patients.
As can be inferred from Table 2, CP patients had sig-
nificantly lower scores on the PANSS total, positive, and 
negative scale at both time points. Symptomatic improvement 
was most marked in the positive symptom cluster. While 
both groups showed symptomatic improvement after 6 weeks 
of treatment, a significant difference was found in PANSS 
cognitive score and in CGI-S for the CP group.
Biochemical parameters
As compared to controls, serum BDNF levels were lowered 
in patients with schizophrenia, and plasma glutamate levels 
appeared to be increased in both patient groups. Concerning 
plasma levels of glycine, significant higher values were found 
in CP patients at both time points as compared to patients with 
schizophrenia as well as control subjects. Also, at both time 
points, plasma tryptophan levels were significantly lower in 
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biochemical parameters, particularly plasma levels of glycine 
and tryptophan. Serum levels of BDNF were significantly 
lower in the schizophrenia group as compared to controls.
With respect to glycine, in CP, plasma levels were 
elevated as compared to both schizophrenia and healthy con-
trols. Although in 2004 Sumiyoshi et al found lowered levels 
of glycine for schizophrenia in comparison with controls and 
patients with major depression, current findings are in line 
with those reported in 2006 by Hoekstra et al in patients with 
bipolar mania.38,39
Since glycine is an essential co-agonist for glutamate at 
the NMDA receptor, increased levels could be regarded as 
a reflection of disturbances in glutamatergic neurotransmis-
sion. With respect to the latter, since plasma glutamate levels 
did not differ significantly between the two groups, it could 
be speculated that in CP, glycine levels are elevated as a 
compensatory reaction to NMDA receptor hypofunction, 
whereas patients with schizophrenia would have insufficient 
neuroplasticity to produce such a response. This hypothesis 
is corroborated by the present lowered serum BDNF levels 
in the schizophrenia group and by other studies showing 
that phencyclidine-induced psychotic symptoms can be 
ameliorated by administration of glycine.40,41 Further sup-
port is found in earlier studies that show beneficial effects 
of adjuvant high-dose glycine augmentation to other anti-
psychotic agents.42–44
In patients with other psychotic disorders, both BDNF 
and glycine levels did not differ from controls. It could be 
speculated that, even in the presence of sufficient neuroplas-
ticity, the ability to adaptively increase glycine levels might 
be characteristic for CP.
Table 3 Blood levels of biochemical parameters in CP, schizophrenia, and controls
CP (n=10) Schizophrenia (n=33) Controls (n=75)
BDNF baseline (μg/L) 20.4±7.1 19.6±5.8*** 24.4±6.7
BDNF 6 weeks (μg/L) 19.9±8.1 19.1±6.0***
HVA baseline (nmol/L) 60.4±21.3 58.5±19.7 53.4±13.7
HVA 6 weeks (nmol/L) 51.8±20.4 52.1±15.8
Glutamate baseline (μmol/L) 56.3±24.8** 69.5±30.5*** 34.4±16.1
Glutamate 6 weeks (μmol/L) 64.9±44.6** 66.2±30.9***
Glycine baseline (μmol/L) 292.2±96.9* 215.1±62.3# 224.2±47.8
Glycine 6 weeks (μmol/L) 280.9±86.2* 223.7±62.3#
Tryptophan baseline (μmol/L) 37.4±14.0** 48.3±11.5# 47.5±7.7
Tryptophan 6 weeks (μmol/L) 38.1±10.8** 43.5±11.7
Trp/LNAAs ratio baseline 7.1±1.4** 7.7±1.5* 8.6±1.5
Trp/LNAAs ratio 6 weeks 7.4±1.6* 7.8±1.7*
Phenylalanine baseline (μmol/L) 52.4±10.2 63.4±15.1*,# 56.3±8.9
Phenylalanine 6 weeks (μmol/L) 51.7±10.1 55.3±11.2
Isoleucine baseline (μmol/L) 69.1±22.1 82.7±32.8 71.0±22.2
Isoleucine 6 weeks (μmol/L) 63.6±19.6 71.8±22.1
Leucine baseline (μmol/L) 121.7±36.0 158.5±60.0* 130.3±32.4
Leucine 6 weeks (μmol/L) 123.3±39.5 136.9±39.2
Valine baseline (μmol/L) 218.7±65.2 267.6±76.1 245.3±56.6
Valine 6 weeks (μmol/L) 218.7±49.8 239.6±58.0
Tyrosine baseline (μmol/L) 61.5±14.9 72.2±25.6 63.9±17.0
Tyrosine 6 weeks (μmol/L) 61.5±18.7 62.1±15.4
Notes: *Difference versus controls (Mann–Whitney U), P,0.05. **Difference versus controls (Mann–Whitney U), P#0.01. ***Difference versus controls (Mann–Whitney U), 
P#0.001. #Difference between schizophrenia and CP (Mann–Whitney U), P,0.05. Data presented as mean ± SD.
Abbreviations: CP, cycloid psychoses; BDNF, brain-derived neurotrophic factor; HVA, homovanillic acid; Trp/LNAAs, tryptophan/large neutral amino acids; SD, standard 
deviation.
Table 4 Blood levels of biochemical parameters in patients with 
other psychotic disorders (n=15) and controls (n=75)
Baseline 6 weeks Controls
BDNF (μg/L) 21.9±8.1 20.4±7.6 24.4±6.7
HVA (nmol/L) 75.5±36.6 63.5±23.3 53.4±13.7
Glutamate (μmol/L) 51.1±13.9* 50.9±16.6* 34.4±16.1
Glycine (μmol/L) 268.5±137.5 263.7±124.9 224.2±47.8
Tryptophan (μmol/L) 47.4±9.6 46.0±7.8 47.5±7.7
Trp/LNAAs ratio 7.9±2.2 8.0±1.6 8.6±1.5
Phenylalanine (μmol/L) 59.8±12.0 58.3±10.4 56.3±8.9
Isoleucine (μmol/L) 81.1±23.1 72.7±22.3 71.0±22.2
Leucine (μmol/L) 149.4±43.2 141.6±38.7 130.3±32.4
Valine (μmol/L) 264.4±52.4 252.1±65.1 245.3±56.6
Tyrosine (μmol/L) 73.7±21.1 70.5±20.7 63.9±17.0
Notes: *Difference versus controls (Mann–Whitney U), P#0.001. Data presented 
as (mean ± SD).
Abbreviations: BDNF, brain-derived neurotrophic factor; HVA, homovanillic acid; 
Trp/LNAAs, tryptophan/large neutral amino acids; SD, standard deviation.
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The observation that plasma levels of glutamate are 
increased in all patient groups as compared to controls is in 
accordance with reports that relate elevated glutamate levels 
with psychosis and psychotic relapse, albeit that decreased 
levels in schizophrenia and bipolar disorders have also been 
reported.29,45,46 Elevated glutamate levels are hypothesized 
to be the result of NMDA receptor hypofunction, leading 
to diminished glutamatergic neurotransmission and to the 
evolvement of schizophrenic symptoms, including negative 
and cognitive symptoms.15,16
The Trp/LNAAs ratio was significantly lower in CP and 
schizophrenia as compared to controls. This finding is sug-
gestive of a decreased central serotonergic activity in both 
patient groups. The lower tryptophan levels in CP might point 
to an increased breakdown of tryptophan via the kynurenine 
pathway. One of the products in this pathway is kynurenic 
acid, which is not only an antagonist of the NMDA receptor 
but also a neuroprotectant.47,48 It could be speculated that 
in CP, other than in schizophrenia, this neuroprotective 
mechanism is still activated which would correspond with 
better neuroplastic properties and a more favorable course 
of disease in CP.
Apart from small sample size and the use of peripheral 
measurements only, a limitation can be identified in that a 
substantial number of patients were treated earlier with a 
wide range of FGA and SGA agents. The latter, however, 
most probably did not interfere with the results, since no 
influences were found regarding medication status in the 
two patient groups.
Conclusion
In both CP and schizophrenia, systemic glutamate metabo-
lism and the Trp/LNAAs ratio were altered, which could be 
related to changes in glutamate signaling. Moreover, differ-
ences in especially glycine between CP and schizophrenia 
were found, which may point at a better neuroplasticity in CP 
than in schizophrenia. This may be in line with better clinical 
outcome in CP. Therefore, it is crucial to identify CP as a 
separate group of disorders within the psychosis spectrum.
Acknowledgments
The authors would like to thank MKF Schneider, MD, PhD, 
for the critical evaluation of diagnoses in all patients and AES 
Sijben, MSc, PhD, for assistance with statistical analyses. The 
authors are indebted to Mrs A Voskuilen-Kooijman from the 
Neuropsychiatric Laboratory of the Department of Clinical 
Chemistry of the Erasmus University Medical Center for 
biochemical analyses.
Disclosure
The authors declare that they have no conflicts of interest 
in this work.
References
 1. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis – 
linking biology, pharmacology and phenomenology of psychosis. 
Schizophr Res. 2005;79:59–68.
 2. Javitt DC, Liederman E, Cienfuegos A, Shelley AM. Panmodal process-
ing imprecision as a basis for dysfunction of transient memory storage 
systems in schizophrenia. Schizophr Bull. 1999;25:763–775.
 3. Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine 
dysregulation in schizophrenia – a synthesis and selective review. 
J Psychopharmacol. 2007;21:440–452.
 4. Möhler H, Rudolph U, Boison D, Singer P, Feldon J, Yee BK. Regulation 
of cognition and symptoms of psychosis: focus on GABA
A
 receptors and 
glycine transporter 1. Pharmacol Biochem Behav. 2008;90:58–64.
 5. Gruber O, Chadha Santuccione A, Aach H. Magnetic resonance imag-
ing in studying schizophrenia, negative symptoms, and the glutamate 
system. Front Psychiatry. 2014;5:32.
 6. Luján R, Shigemoto R, López-Bendito G. Glutamate and GABA receptor 
signaling in the developing brain. Neuroscience. 2005;130:567–580.
 7. Manent JB, Represa A. Neurotransmitters and brain maturation: early 
paracrine actions of GABA and glutamate modulate neuronal migration. 
Neuroscientist. 2007;13:268–279.
 8. Stone JM. Glutamatergic antipsychotic drugs: a new dawn in the treat-
ment of schizophrenia? Ther Adv Psychopharmacol. 2011;1:5–18.
 9. Veerman SRT, Schulte PFJ, De Haan L. The glutamate hypothesis: 
a pathogenic pathway from which pharmacological interventions have 
emerged. Pharmacopsychiatry. 2014;47:121–130.
 10. De Bartolomeis A, Sarappa C, Magara S, Iasevoli F. Targeting the 
glutamate system for novel antipsychotic approaches: relevance for 
residual psychotic symptoms and treatment resistant schizophrenia. 
Eur J Pharmacol. 2012;682:1–11.
 11. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of 
schizophrenia. Am J Psychiatry. 1991;148:1301–1308.
 12. Dandash O, Harrison BJ, Adapa R, et al. Selective augmentation of 
striatal functional connectivity following NMDA receptor antagonism: 
implications for psychosis. Neuropsychopharmacology. 2015;40(3): 
622–631.
 13. Gordon JA. Testing the glutamate hypothesis of schizophrenia. Nat 
Neurosci. 2010;13:2–4.
 14. Javitt DC. Twenty-five years of glutamate in schizophrenia: are we 
there yet? Schizophr Bull. 2012;38:911–913.
 15. Schmitt A, Hasan A, Gruber O, Falkai P. Schizophrenia as a disorder 
of disconnectivity. Eur Arch Psychiatry Clin Neurosci. 2011;261: 
S150–S154.
 16. Zink M, Englisch S, Schmitt A. Antipsychotic treatment modulates glu-
tamate transport and NMDA receptor expression. Eur Arch Psychiatry 
Clin Neurosci. 2014;264:S67–S82.
 17. World Health Organization. The ICD-10 Classification of Mental and 
Behavioural Disorders. Clinical Descriptions and Diagnostic Guide-
lines. Geneva: World Health Organization; 1992.
 18. Leonhard K. Classification of endogenous psychoses and their dif-
ferentiated etiology. New York, Springer Wien; 1999.
 19. Perris C, Brockington IF. Cycloid psychoses and their relation to the 
major psychoses. In: Perris C, Struwe D, Jansson B, editors. Biological 
Psychiatry. Amsterdam: Elsevier; 1981:447–450.
 20. Jabs BE, Pfuhlmann B, Bartsch AJ, Cetkovich-Bakmas MG, Stöber G. 
Cycloid psychoses – from clinical concepts to biological foundations. 
J Neural Transm. 2002;109:907–919.
 21. Beckmann H, Franzek E. Cycloid psychoses and their differentiation 
from affective and schizophrenic psychoses. In: Henn F, Sartorius N, 
Helmchen H, Lauter H, editors. Contemporary Psychiatry Volume 3. 
Heidelberg: Springer Verlag; 2001:387–398.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
62
.1
63
.1
07
.5
0 
on
 2
4-
Se
p-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal 
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS, 
and is the official journal of The International Neuropsychiatric 
 Association (INA). The manuscript management system is completely 
online and includes a very quick and fair peer-review system, which 
is all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.
Neuropsychiatric Disease and Treatment 2016:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1933
Biochemistry of cycloid psychoses
 22. Jabs BE, Krause U, Althaus G, Bartsch AJ, Stöber G, Pfuhlmann B. 
Differences in quality of life and course of illness between cycloid and 
schizophrenic psychoses – a comparative study. World J Biol Psychiatry. 
2004;5:136–142.
 23. Salvatore P, Bhuvaneswar C, Ebert D, Maggini C, Baldessarini, RJ. 
Cycloid psychoses revisited: case reports, literature review, and com-
mentary. Harv Rev Psychiatry. 2008;16:167–180.
 24. American Psychiatric Association. Diagnostic and Statistic Manual 
of Mental Disorders (4th ed). Washington, DC: American Psychiatric 
Association; 1994.
 25. Lindvall M, Axelsson R, Öhman, R. Incidence of cycloid psychosis: a 
clinical study of first-admission psychotic patients. Eur Arch Psychiatry 
Clin Neurosci. 1993;242:197–202.
 26. Pfuhlmann B. Das Konzept der zykloiden Psychosen [The concept 
of cycloid psychoses]. Fortschr Neurol Psychiatr. 1998;66:1–9. 
German.
 27. Peralta V, Cuesta MJ. Cycloid psychosis: a clinical and nosological 
study. Psychol Med. 2003;33:443–453.
 28. Peralta V, Cuesta MJ. Cycloid psychosis. Int Rev Psychiatry. 2005;17: 
53–62.
 29. Van der Heijden FM, Tuinier S, Fekkes D, Sijben AES, Kahn RS, 
Verhoeven WMA. Atypical antipsychotics and the relevance of gluta-
mate and serotonin. Eur Neuropsychopharmacol. 2004;14:259–265.
 30. Van de Kerkhof NW, Van der Heijden FM, Schneider MK, et al. 
Cycloid psychoses: Leonhard’s descriptions revisited. Eur J Psychiatry. 
2012;26:266–278.
 31. Andreasen NC, Flaum MC, Arndt S. The comprehensive assessment of 
symptoms and history (CASH): an instrument for assessing diagnosis 
and psychopathology. Arch Gen Psychiatry. 1992;49:615–623.
 32. Kay SR, Fiszbein A, Opfer L. The positive and negative syndrome scale 
(PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
 33. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. 
Bethesda, MD: National Institute of Mental Health; 1976.
 34. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor 
model of schizophrenia: initial validation. J Nerv Ment Dis. 1994;182: 
631–638.
 35. Leonhard K. Differenzierte Diagnostik der endogenen Psychosen, 
abnormen Persönlichkeitsstrukturen und neurotischen Entwicklun-
gen. [Differential diagnostics of endogenous psychoses, abnormal 
personality structures and neurotic development] 4th ed. Berlin: Verlag 
Gesundheit GmbH; 1991.
 36. Skodol AE, Rosnick L, Kellmann D, Oldham JM, Hyler S. Develop-
ment of a procedure for validating structured assessment of axis II. In: 
Oldham JM, editor. Personality Disorders: New Perspectives on Diagnos-
tic Validity. Washington, DC: American Psychiatric Press; 1991:43–70.
 37. Fekkes D, Van Dalen A, Edelman M, Voskuilen A. Validation of the 
determination of amino acids in plasma by high-performance liquid chro-
matography using automated pre-column derivatization with o-phthal-
dialdehyde. J Chromatogr B Biomed Appl. 1995;669(2):177–186.
 38. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY. 
Plasma glycine and serine levels in schizophrenia compared to normal 
controls and major depression: relation to negative symptoms. Int 
J Neuropsychopharmacol. 2004;7:1–8.
 39. Hoekstra R, Fekkes D, Loonen AJM, Pepplinkhuizen L, Tuinier S, 
Verhoeven WMA. Bipolar mania and plasma amino acids: increased 
levels of glycine. Eur Neuropsychopharmacol. 2006;16:71–77.
 40. D’Souza DC, Singh N, Elander J, et al. Glycine transporter inhibitor 
attenuates the psychomimetic effects of ketamine in healthy males: pre-
liminary evidence. Neuropsychopharmacology. 2012;37:1036–1046.
 41. Woods SW, Walsh BC, Hawkins KA, et al. Glycine treatment of the 
risk syndrome for psychosis: report of two pilot studies. Eur Neurop-
sychopharmacol. 2013;23:931–940.
 42. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. 
Double-blind, placebo-controlled, crossover trial of glycine adju-
vant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 
1996;169:610–617.
 43. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. 
Efficacy of high-dose glycine in the treatment of enduring negative 
symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56:29–36.
 44. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-
dose glycine added to olanzapine and risperidone for the treatment of 
schizophrenia. Biol Psychiatry. 2004;55:165–171.
 45. Ivanova SA, Boyko AS, Fedorenko OY, Krotenko NM, Semke AV, 
Bokhan NA. Glutamate concentration in the serum of patients with 
schizophrenia. Procedia Chem. 2014;10:80–85.
 46. Palomino A, González-Pinto A, Aldama A, et al. Decreased levels 
of plasma glutamate in patients with first-episode schizophrenia and 
bipolar disorder. Schizophr Res. 2007;95:174–178.
 47. Anderson G, Maes M. Schizophrenia: linking prenatal infection to 
cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA 
receptor hypofunction, neurodevelopment and neuroprogression. Prog 
Neuropsychopharmacol Biol Psychiatry. 2013;42:5–19.
 48. Hashimoto K. Targeting of NMDA receptors in new treatments for 
schizophrenia. Expert Opin Ther Targets. 2014;18:1049–1063.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
62
.1
63
.1
07
.5
0 
on
 2
4-
Se
p-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
